Relationship between the expression levels of TET methylcytosine dioxygenase 2 and DNA methyltrans-ferase 3A and the classification and prognosis of myelodysplastic syndromes
Objective To explore the relationship between the gene expression levels of TET methylcy-tosine dioxygenase 2(TET2)and DNA methyltransferase 3 A(DNMT3A)and the clinical classification and prognosis of patients with myelodysplastic syndromes(MDS).Methods A total of 97 patients with MDS admitted to Shijiazhuang People's Hospital,Heibei Province from January 2015 to December 2022 were retrospectively selected as the observation group,and 90 people without blood system diseases in the same hospital during the same period of physical examination were selected as the control group,and 87 patients with aplastic anemia were selected as the similar control group.The expression levels of TET2 and DNMT3A genes in the three groups were compared,and the differences of gene expression levels in patients with different MDS types and prognostic grades were compared.Results The expression level of TET2 gene in the observation group was lower than those in the control group and similar control group,and the expression level of DNMT3A gene was higher than those in the control group and similar control group(all P＜0.001).However,there was no significant difference between patients with different types of MDS(all P＞0.05).With the increase of prognosis risk,the expression level of TET2 gene showed an overall downward trend,and the expression level of DNMT3A gene showed an overall upward trend(all P＜0.001).The expression level of TET2 gene was negatively correlated with the poor prognosis of MDS(r=-0.664,P＜0.001),and the expression level of DNMT3A gene was positively correlated with the poor prognosis of MDS(r=0.639,P＜0.001).Conclusion The expression levels of TET2 and DNMT3A genes are not significantly different among different types of MDS,but are significantly related to the prognosis of MDS,and have reference significance for the prognosis of patients in clinic.
万方数据
维普
